sb 203580 has been researched along with losartan potassium in 6 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | sb 203580 (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bittorf, T; Kósa, F; Magócsi, M; Marotzki, S; Marquardt, H; Ramirez-Chávez, Y; Rosche, A; Schaefer, A | 1 |
| Du, F; Gong, Q; Ke, Y; Qian, ZM; Wu, XM; Yung, WH; Zhu, L | 1 |
| Kambe, T; Kim, WJ; Moon, SK; Nagao, M; Park, SL; Song, JH; Won, SY | 1 |
| Agafonov, VI; Chaikovskii, AV; Dygai, AM; Khrichkova, TY; Minakova, MY; Miroshnichenko, LA; Sherstoboev, EY; Simanina, EV; Stavrova, LA; Udut, EV; Zhdanov, VV; Zyuz'kov, GN | 1 |
| Hong, L; Huang, Z; Li, H; Miao, B; Na, N; Zhang, J; Zhao, D | 1 |
| Duan, Y; Jin, Z; Song, Y; Wang, L; Wu, F | 1 |
6 other study(ies) available for sb 203580 and losartan potassium
| Article | Year |
|---|---|
Opposite effects of inhibitors of mitogen-activated protein kinase pathways on the egr-1 and beta-globin expression in erythropoietin-responsive murine erythroleukemia cells.
Topics: Animals; Butadienes; DNA-Binding Proteins; Early Growth Response Protein 1; Enzyme Inhibitors; Erythropoietin; Flavonoids; Gene Expression Regulation, Neoplastic; Globins; Imidazoles; Immediate-Early Proteins; Leukemia, Erythroblastic, Acute; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-fos; Pyridines; Transcription Factors; Tumor Cells, Cultured | 2004 |
Neuroprotective effect of ligustilide against ischaemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801.
Topics: 4-Butyrolactone; Animals; Cell Line; Chromones; Erythropoietin; Flavonoids; Gene Expression Regulation; Glucose; Imidazoles; L-Lactate Dehydrogenase; Male; Morpholines; Neurons; Oxygen; Plasmids; Pyridines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Repressor Proteins; Transcription Factors | 2011 |
EPO gene expression promotes proliferation, migration and invasion via the p38MAPK/AP-1/MMP-9 pathway by p21WAF1 expression in vascular smooth muscle cells.
Topics: Cell Cycle Proteins; Cell Line; Cell Movement; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Erythropoietin; Humans; Imidazoles; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Smooth Muscle; NF-kappa B; Oncogene Proteins; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1 | 2015 |
Role of PI3K, MAPK/ERK 1/2, and p38 in Production of Erythropoietic Activity by Bone Marrow Cells after Blood Loss.
Topics: Anemia; Animals; Bone Marrow Cells; Chromones; Disease Models, Animal; Erythropoiesis; Erythropoietin; Flavonoids; Gene Expression Regulation; Hemorrhage; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Signal Transduction | 2016 |
Renoprotective effect of erythropoietin via modulation of the STAT6/MAPK/NF-κB pathway in ischemia/reperfusion injury after renal transplantation.
Topics: Acetylcysteine; Animals; Anthracenes; Apoptosis; Erythropoietin; Gene Expression Regulation; Humans; Imidazoles; Interferon-gamma; Kidney; Kidney Transplantation; Lentivirus; MAP Kinase Kinase 4; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyridines; Pyrimidines; Rats; Reperfusion Injury; RNA, Small Interfering; Signal Transduction; STAT6 Transcription Factor | 2018 |
Erythropoietin induces the osteogenesis of periodontal mesenchymal stem cells from healthy and periodontitis sources via activation of the p38 MAPK pathway.
Topics: Adult; Cell Differentiation; Cell Proliferation; Erythropoietin; Female; Humans; Imidazoles; Male; Mesenchymal Stem Cells; Middle Aged; Osteogenesis; p38 Mitogen-Activated Protein Kinases; Periodontal Ligament; Periodontitis; Primary Cell Culture; Pyridines; Signal Transduction | 2018 |